Physician profile
John V Timko
NPI 1700992948
$151,804.55
in general payments reported to CMS, 2019-2025
31 companies · $47K in 2025
The $47K reported for 2025 was more than what 98% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $6,132 · 2020: $3,625 · 2021: $6,756 · 2022: $7,446 · 2023: $29K · 2024: $52K · 2025: $47K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $118K · Food and Beverage: $9,548 · Education: $235 · Travel and Lodging: $220.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $117,842.00 |
| Food and Beverage | $9,548.12 |
| Education | $235.13 |
| Travel and Lodging | $219.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $141,677.23 | 2019-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Alkermes, INC. | $1,429.16 | 2019-2025 | Lybalvi, Aristada |
| Takeda Pharmaceuticals U.S.A., INC. | $1,074.88 | 2019-2025 | Trintellix |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,039.11 | 2020-2025 | Caplyta |
| Abbvie INC. | $997.76 | 2021-2025 | Vraylar |
| Lundbeck LLC | $915.69 | 2019-2025 | Rexulti |
| Neurocrine Biosciences, INC. | $783.68 | 2019-2025 | Ingrezza |
| Teva Pharmaceuticals USA, INC. | $486.24 | 2019-2025 | Austedo Xr, Austedo Xr, Austedo |
| Corium, LLC | $438.10 | 2022-2024 | Azstarys |
| Vanda Pharmaceuticals INC. | $393.22 | 2019-2025 | Fanapt |
| Axsome Therapeutics, INC. | $380.73 | 2022-2025 | Auvelity, Sunosi |
| Ironshore Pharmaceuticals INC. | $350.87 | 2019-2024 | Jornay Pm |
| E.R. Squibb & Sons, L.L.C. | $245.43 | 2024-2025 | Cobenfy |
| Sunovion Pharmaceuticals INC. | $228.03 | 2021 | |
| Allergan, INC. | $224.82 | 2019-2020 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Almatica Pharma LLC | $206.07 | 2022-2024 | Loreev Xr, Gralise |
| Supernus Pharmaceuticals, INC. | $191.60 | 2022-2023 | Qelbree |
| Janssen Pharmaceuticals, INC | $163.23 | 2019-2023 | Spravato |
| Shire North American Group INC | $137.48 | 2019 | |
| Acadia Pharmaceuticals INC | $99.79 | 2019-2022 | |
| Idorsia Pharmaceuticals US INC | $79.21 | 2022-2024 | Quviviq |
| Adlon Therapeutics L.P. | $47.11 | 2020 | |
| Vertical Pharmaceuticals, LLC | $45.65 | 2024 | Relexxii |
| Merck Sharp & Dohme LLC | $35.75 | 2022-2023 | Belsomra |
| Bausch Health US, LLC | $30.17 | 2022 | |
| Collegium Pharmaceutical, INC. | $21.79 | 2025 | Jornay Pm |
| Sage Therapeutics, LLC | $18.18 | 2019 | |
| Harmony Biosciences LLC | $17.53 | 2025 | |
| Neos Therapeutics, LP | $16.45 | 2022 | |
| Jazz Pharmaceuticals INC. | $15.55 | 2019 | |
| Neuronetics, INC. | $14.04 | 2023 | Neurostar Tms Therapy System |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Timko listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.